Optimal personalised treatment of early breast cancer using multiparameter ... | Recruiting
Optimal personalised treatment of e... | Recruiting
Optimal personalised treatment of early breast cancer using multiparameter analysis
OPTIMA

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Topic: National Cancer Research Network
  • Subtopic: Breast Cancer
  • Disease: Breast
Primary Contact Details
Recruitment Status
Recruiting
Trial source and source ID number
ISRCTN42400492
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
http://cancerhelp.cancerresearchuk.org/trials/a-trial-looking-predict-when-chemotherapy-needed-breast-cancer-optima
Research Details
  • The OPTIMA trial seeks to advance the development of personalised medicine in breast cancer by using multi-parameter tests to identify those women who are likely to benefit from chemotherapy and sparing those who are unlikely to benefit from an unnecessary and unpleasant treatment. The OPTIMA study population would ordinarily be treated with a combination of chemotherapy and endocrine therapy. The trial compares the management of patients using test-directed assignment to chemotherapy with standard management (chemotherapy) in a non-inferiority design. OPTIMA prelim is the preliminary phase of the study which will select the testing technology to be used in the main trial and demonstrate whether the main trial is feasible.

    Preliminary study objectives:
    1. To evaluate the performance and health-economics of alternative multiparameter tests to determine which technology(s) should be evaluated in the main trial.
    2. To establish the acceptability to patients and clinicians of randomisation to test-directed treatment assignment.
    3. To establish efficient and timely sample collection and analysis essential to the delivery of multi-parameter test driven treatment.

    Main trial objectives:
    1. To identify a method of selection that reduces chemotherapy use for patients with hormone sensitive primary breast cancer without detriment to recurrence and survival.
    2. To establish the cost-effectiveness of test-directed treatment strategies compared to standard practice.

    More details can be found at http://www.nets.nihr.ac.uk/projects/hta/103401 and http://www.nets.nihr.ac.uk/projects/hta/1034501
Phase
Not Applicable
Study Design
Randomised; Interventional; Design type: Diagnosis
Study Type
Interventional
Intervention

Control: Chemotherapy followed by endocrine therapy
Experimental: Test directed assignment of chemotherapy or not, followed by endocrine therapy
Follow up length: 10 years

Intervention Type
Other
Primary Outcome Measures
    OPTIMA prelim:
    1. Identification of a multi-parameter test technology that is suitable for validation in the main study.
    2. Recruitment of 300 patients in not more than 2 years from the first centre opening to recruitment, and, for the final 150 patients:
    2.1. Patient acceptance rate will be at least 40%
    2.2. Recruitment will take no longer than 6 months
    2.3. Chemotherapy will start within 6 weeks of signing the OPTIMA consent form for no less than 85% of chemotherapy assigned patients.

    Main trial:
    1. Invasive disease free survival (IDFS) non-inferiority of test-directed chemotherapy treatment and endocrine therapy compared to chemotherapy followed by endocrine treatment
    2. Cost effectiveness evaluation of protocol specified multi-parameter assay driven treatment against standard clinical practice
Secondary Outcome Measures
    Current secondary outcome measures as of 29/09/2015:
    Main trial:
    1. Distant disease free survival (DDFS)
    2. Breast cancer specific survival (BCSS) and Overall survival (OS)
    3. IDFS for patients with low risk patients with low-risk tumours
    4. Quality of life and health resource use as measured by EQ-5D & FACT-B
    5. Patient compliance with long term endocrine therapy

    Previous secondary outcome measures:
    Main trial:
    1. Quality of life and health resource use as measured by EQ-5D & FACT-B
    2. Distant disease free survival
    3. Comparative performance of multi-parameter assays (if more than one adopted)
    4. Patient compliance to long term endocrine therapy
    5. Overall survival (OS)
Publication(s)
2016 results in: https://www.ncbi.nlm.nih.gov/pubmed/26867046
Result Reports
Sorry, this information is not available
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Both
Age Range
Adult
Who Can Participate
Patient
Number of Participants
OPTIMA prelim : 300 (plus 200 extension), main trial: 4500
Participant Inclusion Criteria
    Current inclusion criteria as of 29/09/2015:
    1. Female or male, age >= 40
    2. Excised invasive breast cancer with local treatment either completed or planned according to trial guidelines.
    3. ER positive (Allred score >=3 or H-score >=10 or >1% of tumour cells stained positive) as determined by the referring site (in a laboratory meeting NEQAS standards).
    4. HER2 negative (IHC 0-1+, or ISH negative/non-amplified (ratio of HER2/chromosome 17 <2.00 and copy number <6)) as determined by the referring site (in a laboratory meeting NEQAS standards).
    5. Axillary lymph node status:
    5.1. 1-9 involved (macrometastases i.e. >2mm) OR
    5.2. Node negative AND tumour size >= 30mm.
    Nodes containing micrometastases (i.e. >0.2-2mm) or isolated tumour cell clusters (ITC) only (i.e. <=0.2mm) will be considered to be uninvolved.
    6. Considered appropriate for adjuvant chemotherapy by treating physician.
    7. Patient must be fit to receive chemotherapy and other trial-specified treatments with no concomitant medical, psychiatric or social problems that might interfere with informed consent, treatment compliance or follow up.
    8. Bilateral cancers are permitted provided at least one tumour fulfils the entry criteria and none meet any of the exclusion criteria.
    9. Multiple ipsilateral cancers are permitted provided at least one tumour fulfils the entry criteria and none meet any of the exclusion criteria.
    10. Written informed consent for the study.

    Previous inclusion criteria:
    1. Female, age >= 40
    2. Excised invasive breast cancer with local treatment either completed or planned according to trial guidelines.
    3. Estrogen Receptor (ER) +ve (Allred score >=3 or Hscore >=10 or as otherwise established by the reporting pathologist) as determined by the referring centre and centrally confirmed.
    4. Human epidermal growth factor receptor 2 (HER2) negative - i.e. IHC 0-1+, or FISH or other ISH nonamplified (HER2 testing in lab meeting NEQAS EQA standards), as determined by the referring centre and centrally confirmed.
    5. Axillary lymph node status:
    5.1. 1-9 involved (macro metastases i.e. >2mm OR micro metastases i.e. >0.22mm) OR
    5.2. Node negative AND tumour size > 30mm. Nodes containing isolated tumour cell clusters (ITC) only, i.e. <=0.2mm diameter, will be considered to be uninvolved.
    6. Considered appropriate for adjuvant chemotherapy by treating physician
    7. Patient must be fit to receive chemotherapy and other trialspecified treatments with no concomitant medical, psychiatric or social problems that might interfere with informed consent, treatment compliance or follow up
    8. Bilateral and multifocal cancers are permitted provided at least one tumour fulfils the entry criteria and none meet any of the exclusion criteria (pathology information must be available for at least 2 tumours).
    9. Negative staging if either clinical suspicion of metastatic disease or high risk (pT >50mm or >=4 involved nodes)
    10. Written informed consent for the study
Participant Exclusion Criteria
    Current exclusion criteria as of 29/09/2015:
    1. >=10 involved axillary nodes (as defined in the inclusion criteria) or involved internal mammary node.
    2. ER negative OR HER2 positive/amplified (as determined by the referring site).
    3. Metastatic disease.
    4. Previous diagnosis of malignancy unless:
    4.1. Managed by surgical treatment only and disease free for 10 years
    4.2. Previous basal cell carcinoma of skin, cervical intraepithelial neoplasia or ductal carcinoma in situ (DCIS) of the breast treated with surgery only or previous diagnosis of lobular carcinoma in situ (LCIS).
    5. The use of oestrogen replacement therapy (HRT) at the time of surgery. Patients who are taking HRT at the time of diagnosis are eligible provided the HRT is stopped before surgery.
    6. Pre-surgical chemotherapy, endocrine therapy or radiotherapy for breast cancer. Treatment with endocrine agents known to be active in breast cancer including ovarian suppression is permitted provided this was completed >1 year prior to study entry.
    7. Commencement of adjuvant treatment prior to trial entry. Short-term endocrine therapy initiated because of, for instance, prolonged recovery from surgery is permitted but must be discontinued at trial entry.
    8. Trial entry more than 8 weeks after completion of breast cancer surgery.
    9. Planned further surgery for breast cancer, including axillary surgery, to take place after randomisation, except either re-excision or completion mastectomy for close or positive/involved margins which may be undertaken following completion of chemotherapy.
    10. Patients with more than two involved axillary nodes (as defined in the inclusion criteria) identified by sentinel node biopsy or by axillary sampling where further axillary surgery is not planned.

    Previous exclusion criteria:
    1. >=10 involved axillary nodes or involved internal mammary node
    2. ER -ve OR HER2 positive/amplified on central eligibility testing
    3. Previous diagnosis of malignancy unless:
    3.1. Managed by surgical treatment only and disease free for 10 years or
    3.2. Previous basal cell carcinoma of skin, cervical intraepithelial neoplasia or in situ ductal carcinoma of the breast treated with surgery only
    4. The use of estrogen replacement therapy (HRT) at the time of surgery. Patients who are taking HRT at the time of diagnosis are eligible provided the HRT is stopped before the day of surgery
    5. Previous chemotherapy, endocrine therapy or radiotherapy for breast cancer. Treatment with endocrine agents known to be active in breast cancer including ovarian suppression is permitted provided this was completed >1 year prior to study entry
    6. Planned further surgery for breast cancer other than either re-excision or completion mastectomy for close margins this may be undertaken following completion of chemotherapy
    7. Patients with more than two involved axillary nodes (as defined in the inclusion criteria) identified by sentinel node biopsy or by axillary sampling who have not undergone further axillary surgery
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Coventry
CV4 7AL
Trial Contact(s)
Primary Trial Contact
Miss Amy Campbell
-
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis: a randomised study
EudraCT Number
Sorry, this information is not available
Funder(s)
  • Health Technology Assessment Programme
Other Study ID Numbers
Protocol number: 11/0479; UKCRN ID: 12255; funder project numbers: HTA 10/34/01, HTA 10/34/501
Sponsor(s)
University College London
Key Dates

Recruitment Start Date

01 Jul 2012

Recruitment End Date

30 Sep 2019

Trial Start Date

01 Jul 2012

Trial End Date

30 Sep 2023

Date added to source

26 Jun 2012

Date updated in source

01 Nov 2016